ME03567B - Biotin za lečenje demijelinizacionih neuropatija - Google Patents
Biotin za lečenje demijelinizacionih neuropatijaInfo
- Publication number
- ME03567B ME03567B MEP-2019-285A MEP2019285A ME03567B ME 03567 B ME03567 B ME 03567B ME P2019285 A MEP2019285 A ME P2019285A ME 03567 B ME03567 B ME 03567B
- Authority
- ME
- Montenegro
- Prior art keywords
- biotin
- demyelinating neuropathies
- treating demyelinating
- treating
- neuropathies
- Prior art date
Links
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 title 2
- 229960002685 biotin Drugs 0.000 title 1
- 235000020958 biotin Nutrition 0.000 title 1
- 239000011616 biotin Substances 0.000 title 1
- 230000003210 demyelinating effect Effects 0.000 title 1
- 230000007823 neuropathy Effects 0.000 title 1
- 201000001119 neuropathy Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Physiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Nutrition Science (AREA)
- Psychiatry (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Magnetic Ceramics (AREA)
- Manufacture, Treatment Of Glass Fibers (AREA)
- Farming Of Fish And Shellfish (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15305437.4A EP3072513A1 (en) | 2015-03-26 | 2015-03-26 | Biotin for treating Amyotrophic lateral sclerosis |
| EP16713833.8A EP3273957B1 (en) | 2015-03-26 | 2016-03-25 | Biotin for treating demyelinating neuropathies |
| PCT/EP2016/056696 WO2016151132A1 (en) | 2015-03-26 | 2016-03-25 | Biotin for treating amyotrophic lateral sclerosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ME03567B true ME03567B (me) | 2020-07-20 |
Family
ID=52779582
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2019-285A ME03567B (me) | 2015-03-26 | 2016-03-25 | Biotin za lečenje demijelinizacionih neuropatija |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US10357480B2 (me) |
| EP (2) | EP3072513A1 (me) |
| JP (1) | JP6752874B2 (me) |
| KR (1) | KR20170131543A (me) |
| CN (2) | CN107405335A (me) |
| AU (1) | AU2016238759B2 (me) |
| BR (1) | BR112017020408A2 (me) |
| CA (1) | CA2980660A1 (me) |
| CY (1) | CY1122374T1 (me) |
| DK (1) | DK3273957T3 (me) |
| EA (1) | EA034394B1 (me) |
| ES (1) | ES2748354T3 (me) |
| HR (1) | HRP20191491T1 (me) |
| HU (1) | HUE046116T2 (me) |
| IL (1) | IL254619B (me) |
| LT (1) | LT3273957T (me) |
| MA (1) | MA41809B1 (me) |
| ME (1) | ME03567B (me) |
| PL (1) | PL3273957T3 (me) |
| PT (1) | PT3273957T (me) |
| RS (1) | RS59149B1 (me) |
| SI (1) | SI3273957T1 (me) |
| SM (1) | SMT201900548T1 (me) |
| WO (1) | WO2016151132A1 (me) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3072513A1 (en) | 2015-03-26 | 2016-09-28 | Medday | Biotin for treating Amyotrophic lateral sclerosis |
| EP3275439A1 (en) | 2016-07-29 | 2018-01-31 | Medday Pharmaceuticals | Method for treating hepatic encephalopathy |
| EP3893823A4 (en) * | 2018-12-11 | 2022-11-02 | Myospots Australia Pty Ltd | Adhesive pad |
| CN112386703A (zh) * | 2020-01-15 | 2021-02-23 | 李启芳 | 治疗als的联合用药物及其应用 |
| US20240082296A1 (en) * | 2020-10-09 | 2024-03-14 | Tx Medic Ab | Treatment of muscle atrophy using dextran sulfate |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5885976A (en) * | 1995-05-08 | 1999-03-23 | Sandyk; Reuven | Methods useful for the treatment of neurological and mental disorders related to deficient serotonin neurotransmission and impaired pineal melatonin functions |
| CN1802170A (zh) | 2002-09-27 | 2006-07-12 | 比奥根艾迪克Ma公司 | 利用IFN－β治疗慢性炎性脱髓鞘性多神经病 |
| US20050249823A1 (en) * | 2003-11-04 | 2005-11-10 | Murphy Tanya K | Methods for the prevention or amelioration of neuropsychiatric and related diseases |
| US7105183B2 (en) * | 2004-02-03 | 2006-09-12 | The Regents Of The University Of California | Chlorite in the treatment of neurodegenerative disease |
| FR2905868B1 (fr) * | 2006-09-18 | 2012-12-21 | Gemac | Composition destinee au traitement de la sclerose laterale amyotrophique |
| BR112012015084A2 (pt) | 2009-12-23 | 2017-03-07 | Lupin Ltd | composição farmacêutica de liberação lenta de iloperidone |
| FR2993780B1 (fr) * | 2012-07-26 | 2015-02-13 | Assist Publ Hopitaux De Paris | Methode de traitement de la sclerose en plaque |
| FR2958166B1 (fr) | 2010-04-06 | 2012-07-13 | Assist Publ Hopitaux De Paris | Compositions pharmaceutiques fortement dosees en biotine |
| JP6152090B2 (ja) * | 2011-04-21 | 2017-06-21 | ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド，ア ボディー コーポレイトＴＨＥ ＲＥＧＥＮＴＳ ＯＦ ＴＨＥ ＵＮＩＶＥＲＳＩＴＹ ＯＦ ＣＯＬＯＲＡＤＯ，ａ ｂｏｄｙ ｃｏｒｐｏｒａｔｅ | 視神経脊髄炎を処置するための組成物および方法 |
| EA201791043A1 (ru) * | 2011-07-13 | 2017-09-29 | Сайтокинетикс, Инк. | Комбинированная терапия бокового амиотрофического склероза |
| WO2014177286A1 (en) | 2013-04-29 | 2014-11-06 | Assistance Publique - Hopitaux De Paris | Biotin for use in treating x-linked adrenoleukodystrophy |
| JP6664956B2 (ja) * | 2015-02-27 | 2020-03-13 | キリンホールディングス株式会社 | 筋分化促進組成物 |
| EP3072513A1 (en) | 2015-03-26 | 2016-09-28 | Medday | Biotin for treating Amyotrophic lateral sclerosis |
-
2015
- 2015-03-26 EP EP15305437.4A patent/EP3072513A1/en not_active Ceased
-
2016
- 2016-03-25 WO PCT/EP2016/056696 patent/WO2016151132A1/en not_active Ceased
- 2016-03-25 JP JP2018500860A patent/JP6752874B2/ja not_active Expired - Fee Related
- 2016-03-25 US US15/561,911 patent/US10357480B2/en not_active Expired - Fee Related
- 2016-03-25 CA CA2980660A patent/CA2980660A1/en not_active Abandoned
- 2016-03-25 CN CN201680018463.8A patent/CN107405335A/zh active Pending
- 2016-03-25 HU HUE16713833A patent/HUE046116T2/hu unknown
- 2016-03-25 LT LT16713833T patent/LT3273957T/lt unknown
- 2016-03-25 ME MEP-2019-285A patent/ME03567B/me unknown
- 2016-03-25 RS RS20191089A patent/RS59149B1/sr unknown
- 2016-03-25 PT PT16713833T patent/PT3273957T/pt unknown
- 2016-03-25 AU AU2016238759A patent/AU2016238759B2/en not_active Ceased
- 2016-03-25 SI SI201630372T patent/SI3273957T1/sl unknown
- 2016-03-25 PL PL16713833T patent/PL3273957T3/pl unknown
- 2016-03-25 MA MA41809A patent/MA41809B1/fr unknown
- 2016-03-25 EP EP16713833.8A patent/EP3273957B1/en active Active
- 2016-03-25 DK DK16713833T patent/DK3273957T3/da active
- 2016-03-25 ES ES16713833T patent/ES2748354T3/es active Active
- 2016-03-25 SM SM20190548T patent/SMT201900548T1/it unknown
- 2016-03-25 HR HRP20191491 patent/HRP20191491T1/hr unknown
- 2016-03-25 EA EA201792124A patent/EA034394B1/ru not_active IP Right Cessation
- 2016-03-25 KR KR1020177030427A patent/KR20170131543A/ko not_active Withdrawn
- 2016-03-25 CN CN202010704334.2A patent/CN111973592A/zh active Pending
- 2016-03-25 BR BR112017020408A patent/BR112017020408A2/pt not_active Application Discontinuation
-
2017
- 2017-09-24 IL IL254619A patent/IL254619B/en active IP Right Grant
-
2019
- 2019-06-25 US US16/451,654 patent/US20190314342A1/en not_active Abandoned
- 2019-11-13 CY CY20191101195T patent/CY1122374T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL244096A0 (en) | Reinforcement for moving an object | |
| GB201505311D0 (en) | Process | |
| IL258211A (en) | Methods for treating muscular dystrophy | |
| GB201500989D0 (en) | Process | |
| IL278247B (en) | mct4 inhibitors to treat the disease | |
| IL254393A0 (en) | Methods for treating diseases associated with pathological changes in protein | |
| GB201502894D0 (en) | Process | |
| IL256116A (en) | geometric | |
| GB201502893D0 (en) | Process | |
| GB201522243D0 (en) | Treatment | |
| GB201506572D0 (en) | Process | |
| GB201501952D0 (en) | Process | |
| GB201507170D0 (en) | Process | |
| GB201501953D0 (en) | Process | |
| GB201500990D0 (en) | Process | |
| GB201503607D0 (en) | Process | |
| GB201501423D0 (en) | Process | |
| PT3273957T (pt) | Biotina para o tratamento de neuropatias desmielinizantes | |
| GB201503635D0 (en) | Process | |
| GB201502814D0 (en) | Process | |
| GB201504948D0 (en) | Process | |
| GB201508841D0 (en) | Treatment | |
| GB201505712D0 (en) | Process | |
| GB201503606D0 (en) | Process | |
| GB201507234D0 (en) | Process |